pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Incidence of HCC after DAA treatments in HCV-infected patients with GT 1b and 2
| No | Age | Sex | GT | Prior HCV Tx | Liver Cirrhosis (Y/N) | CTP class | MELD score | AFP (ng/ml) | HCC Treatment Maneuver | Treatment regimen | Time to HCC incidence after end of treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC occurrence | |||||||||||
| 1 | 75 | M | 2 | - | N | - | - | 3.9 | - | SOF + R, relapse ETR (+) after GLE/PIB | 1 month after GLE/PIB |
| 2 | 76 | M | 1b | - | N | - | - | 66.1 | - | DCV + ASV SVR12 (+) | 21 months |
| 3 | 65 | M | 1b | PR | Y | A | 8 | 12.5 | - | LDV/SOF + RBV SVR12 (+) | 26 months |
| 4 | 74 | M | 2 | PR | Y | A | 10 | 3.7 | - | SOF + RBV Incomplete, AE | 22 months |
| 5 | 58 | M | 2 | - | Y | A | 7 | 51.5 | - | SOF + RBV SVR12 (+) | 20 months |
| 6 | 66 | M | 1b | - | Y | A | 12 | 42.7 | - | DCV + ASV Incomplete, F/U loss | 15 months |
| 7 | 66 | F | 2 | - | Y | A | 9 | 11.1 | - | SOF + RBV ETR (+) | 1 months |
| HCC recurrence | |||||||||||
| 1 | 68 | M | 1b | PR | Y | A | 14 | 10.3 | Surgical resection | LDV/SOF + RBV SVR12 (+) | 16 months |
| 2 | 74 | M | 1b | - | Y | A | 7 | 5.9 | TACE | DCV + ASV SVR12 (+) | 17 months |
| 3 | 56 | M | 2 | - | N | - | - | 2.2 | Surgical resection | SOF + RBV ETR (+) | 2 months |
| 4 | 75 | F | 2 | - | Y | A | 8 | 5.4 | TACE | SOF + RBV ETR (+) | At the end of treatment |
| 5 | 74 | M | 2 | - | Y | B | 13 | 85.6 | RFA | SOF + RBV SVR12 (+) | 2 months |
| 6 | 73 | M | 1b | - | Y | B | 14 | 2.4 | Surgical resection, TACE, RFA | LDV/SOF + RBV ETR (+) | On treatment |
AE, adverse event; AFP, α-fetoprotein; ASV, asunaprevir; CTP, Child-Turcotte-Pugh; DAA, direct acting antiviral; DCV, daclatasvir; ETR, end-of-treatment response; F, female; GLE/PIB, glecaprevir/pibrentasvir; GT, genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LDV/SOF, ledipasvir/sofosbuvir; M, male; MELD, model for end stage liver disease; N, no; PR, peg-interferon + ribavirin; RBV, ribavirin; RFA, radio-frequency ablation; SOF, sofosbuvir; SVR12, sustained virological response at 12 week; TACE, transarterial chemoembolization; Tx, treatment; Y, yes.